Presented by
Management Forum
Real World Evidence (RWE), Real World Data (RWD) and the Application of Artificial Intelligence (AI) in The Pharmaceutical Market In-house Training
A deep dive into the importance of real world evidence (RWE), real world data (RWD) and artificial intelligence (AI) in pharmaceuticals.
- Format: Live online
- CPD: 6 hours for your records
- Certificate of completion
- The Advancement of Research and Development (R&D) Clinical Trials using Software Automation
- The Importance of Patient Adherence Data and How Digital Tools Can Improve Patient Outcomes
- Building Better Health via Digitalised and Personalised Patient Support Programmes
- Real World Evidence (RWE), Real World Data (RWD) and the Application of Artificial Intelligence (AI) in The Pharmaceutical Market
Course overview
Data drives business and all decision making. We need to be aware of its capacity to inform, lead and deliver insights which can be amplified via artificial intelligence (AI). Data is the fuel; AI is the vehicle. The quest for additional quantitative and qualitative data is boundless and will not relent. All sources should be explored including primary, secondary, pharmacy, community and cursory. This is a dynamic field which will need to be carefully navigated. With increased data, invariably conversations look at the impact of AI. In this course, you will explore the business case for adopting the risk versus reward profile to place your organisation at the heart of the latest thinking.
During the course, you will be able to delve deep into the importance of real world evidence (RWE), real world data (RWD) and explore where new data can add value to your organisation.
Browse our extensive selection of Life Sciences training courses for industry-leading insights into a range of topics. These include Medical Devices, IVDs, Biotech and Biopharma, Animal Health and Pharmaceutical training courses.
Benefits of attending
- Learn who the key contacts and players are
- Understand which direction the industry is moving in
- Explore timelines
- Know the patient groups and organisations
- Gain an insight into the UK, EU and USA perspective
Who should attend?
The content will be applicable to the following biopharmaceutical professionals who help to design, develop and manage a clinical study from inception to commercialisation:
- VPs and managers
- Strategic leaders
- Data scientists and analysts
- Feasibility teams
- Study sets
- Clinical operations
- Regulatory
- Medical affairs
- IT and system integration
- Market access
- Pharmacovigilance and safety
- Diversity and inclusivity teams
- Finance teams and budget holders
From Inception to Commercialisation: A New Approach to Clinical Trials
Dive into our innovative series that explores how digital technologies are transforming each stage of clinical trials and commercial drug delivery. This comprehensive series features four stand-alone courses, each focusing on key technological advancements and their applications:
- The Advancement of Research and Development (R&D) Clinical Trials using Software Automation
- The Importance of Patient Adherence Data and How Digital Tools Can Improve Patient Outcomes
- Building Better Health via Digitalised and Personalised Patient Support Programmes
- Real World Evidence (RWE), Real World Data (RWD) and The Application of Artificial Intelligence (AI) in The Pharmaceutical Market
For a complete understanding of the clinical trial process, you can take advantage of our discounted rate when booking multiple courses. Please contact us at info@ipi.academy to find out more.
This course will cover:
The current landscape
- What are the current pain points prevalent across multi-national biopharma organisations
- Areas of improvement, shared learning and insights
- A deep dive into the drivers for change and the benefits of "new thinking" and aligned digital solutions
Case studies
- Discuss several user cases which will help to solidify, support and amplify best practice
Overview of digital solutions
- Strategy and innovation
- Product review and performance metrics
- Associated costs and business proposition, including return on investment (ROI) guidance and vendor assessment
- Selection questions
1 hour Q&A and recap
Graham Howieson
G7 Consultants Ltd
Graham Howieson is a pharmaceutical business development consultant, inventor and entrepreneur. He is a highly experienced and competent leader, with an International pedigree covering UK, EU, USA and Asia. An industry pioneer with a forward thinking approach to design and the delivery of new innovative drug delivery and smart packaging solutions for over twenty five years. He has worked extensively and exclusively within the pharmaceutical space, with leading global enterprises such as: Glaxo Smith Kline, Astra Zeneca, Johnson and Johnson and Sanofi – building value by solving technical, engineering, regulatory, compliance and brand communication related issues. He has worked to fulfil a client brief, in terms of the budget, timeline and return on investment for commercial use.
Alongside this, he has acquired a range of specialist skills which encompass the development of new, emerging technologies to improve the delivery of clinical trials. Areas of interest include: intellectual property, digital engagement, bespoke software, SaaS, automation, AI, machine learning, remote compliance monitoring, patient engagement/retention, omni-channel communication, wearables, video enablement tools, VR, hybrid and virtual (supply chain) modelling. The primary objective with all technological advances is to achieve process improvement and increased speed of delivery, aligned with a multi-sensory patient experience.
